Leukemia Lymphoma Society: An Invitation to Innovation
Report
TRAIN Central StationFollow
Mar. 10, 2010•0 likes•641 views
Leukemia Lymphoma Society: An Invitation to Innovation
Mar. 10, 2010•0 likes•641 views
Download to read offline
Report
Health & Medicine
Business
Leukemia Lymphoma Society: An Invitation to Innovation - as presented at the Partnering for Cures meeting, December 2, 2009, New York
TRAIN Central StationFollow
Recommended
Oncogenicity Scoring in VSClinicalGolden Helix
Pukana partners biotech entrepreneurshipMark Ahn, PhD
Introducing VSClinical AMP Guidelines: A Comprehensive Workflow for NGS Testi...Golden Helix
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...Golden Helix
Beacon Biomedical AIC PresentationScott Kelly
Bad Luck vs Peto's Paradox in Caner incidencesChi-Ping Day
More Related Content
What's hot
A User’s Perspective: ACMG Guidelines for CNVs in VSClinicalGolden Helix
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline WorkflowGolden Helix
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB UpdatesGolden Helix
BIO 2010 Partnering with PatientsTRAIN Central Station
Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...Golden Helix
VSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP GuidelinesGolden Helix
Similar to Leukemia Lymphoma Society: An Invitation to Innovation
An Overview of Kancure, LLCruchi202
Quantum ImmunlogicsPro-Active Capital Resources Group
BIO 2010 Partnering with PatientsTRAIN Central Station
Islet Investor Presentation Oct 2016 Global Online Growth ConferenceRedChip Companies, Inc.
Dendreon.Finalsarahmerlen
Snti 102013RedChip Companies, Inc.
More from TRAIN Central Station
Valley of Death CAN Briefing SlidesTRAIN Central Station
Pharma Assets PortalTRAIN Central Station
Valley of Death Panel Slides at the Partnering for Cures Conference, December...TRAIN Central Station
Progeria Research Foundation at Partnering for CuresTRAIN Central Station
PATH Malaria Vaccine InitiativeTRAIN Central Station
Life Raft Group: A New Model for Cancer ResearchTRAIN Central Station
Recently uploaded
Early Childhood Focus Group PresentationChesapeakeVirginiaWe
Fluid optimization in selected ICU situationsEmad Zarief Kamel
PHYSIOTHERAPY MANAGEMENT IN DOWN SYNDROMismailabinji
OVERVIEW OF ANTIMICROBIAL STEWARDSHIPTanveerRehman4
ROJoson PEP Talk: Breast Cancer Awareness Month - 2023Reynaldo Joson
Let's Talk About It: Ovarian Cancer - Toxic Positivitybkling
Leukemia Lymphoma Society: An Invitation to Innovation
- 1. An Invitation to Innovation! Louis J DeGennaro, PhD Executive Vice President Chief Scientific Officer The Leukemia & Lymphoma Society
- 2. Anyone can get blood cancer In 2009: One million North Americans
- 3.
- 4.
- 5. Research Value Proposition: CML & Gleevec 5yr survival 55% Lives Saved 90%
- 6. The Pathway to Therapies New Therapies! Research Grant Program Therapy Acceleration Program Discovery Development Commercialize 7 - 10 years ?
- 7. Grant Portfolio Overview by Disease $68 MM; 400 active projects $21.2 MM (32.4)% $4.3 MM (6.6)% $8.5 MM (13.0%) $3.6 MM (5.4%) $28 MM (42.7%) Leukemia Lymphoma Myeloma Basic Biology Gen IM/SCT
- 8.
- 9. LLS Therapeutic Pipeline Discovery Preclinical Phase I Phase II Phase III Patients Lymphoma - PTLD Acute Leukemia - AML Lymphoma – CLL, FL Lymphoma - CLL Acute Leukemia Lymphoma AML Multiple Trials Novel Drug Delivery Multiple Project Analysis Repurposed drug novel indication Antisense Inhibitor Small Molecule Engineered Immunotherapy Vaccine
- 10.
- 11.
- 12. An Invitation to Innovation! Louis J DeGennaro, PhD Executive Vice President Chief Scientific Officer The Leukemia & Lymphoma Society
- 13. Understanding the unmet needs 27 86% 1,300 8,500 HL 70 60% Children 15% Adults 9,000 12,800 AML 104 69% 19,000 63,000 NHL 56 35% 10,600 20,500 MM 28 90% Children ~50% Adults 1,400 5,800 ALL 55 79% 4500 15,500 CLL 42 89% 500 5,000 CML Drugs in development 5 year overall survival rate Deaths per year New cases per year
- 14. Significant Market Opportunity in Blood Cancers Global Sales by Indication (US$ Billions) Current Reported Sales Followed by Estimates for 2010 (US$ Billions) Per Espicom Business Intelligence 22.728 15.485 7.626 Total 1.265 .995 .493 ALL, MDS, Hodgkin’s 5.585 3.674 1.661 CML 3.814 2.943 .965 Multiple Myeloma .941 .262 .152 AML 5.538 3.937 2.695 NHL 5.585 3.674 1.661 CLL 2012 est. 2009 est. 2005 Indication 1.203 WW sales 4.646 WW sales 7 3.2 .265 US only 2.852 .102 2.6 Velcade Rituxan Sprycel Gleevec
- 15.
- 16. Portfolio by Target, Mechanism & Modality 0 10 20 30 40 50 60 70 80 Tyrosine Kinase Kinase (Not Tyrosine) Methyl/Acetyl Anti-sense Diagnostic/Biomarker Transcription Cell Cycle Cell Division Apoptosis Small Molecule Antibody Vaccine Immunotherapy Transplant Stem Cell Cell Processes Targeted Therapy Treatment Modality
- 17. Portfolio Disease Detail HL NHL CLL, SLL General LY AML CML ALL OM General L Myeloma Gen IM/SCT Basic Biology Dollars Funded in Millions $40 $35 $25 $15 $20 $5 $10 $0 $30 44.9% 34.2% 15% 5.9% % $ Disease $5 $10 $15 $20 $25 $30 $35 $40
- 18. Development Project Portfolio 21 2 1 2 2 3 Scale Up IND Prep Tox Form Dev PK & ADME Med Chem IND Sub In vivo POP 21 Clinical Trials 10 1 62 Pipeline projects 28 on Watch List 26 Grants in 2009 with potential to move into development ~350 Discovery Projects THERAPIES
Editor's Notes
- The following graph is a 5 year survival curve of newly diagnosed CML patients. On standard chemotherapy only 55% survive to the 5 yr mark. However on Gleevec, a targeted therapy, nearly 95% of patients survive. The shift in this graph represents lives saved. And, the Society supported Dr. Brian Druker and others as they developed this revolutionary new “targeted” drug, and continues to support further improvements ~ 20,000 patients diagnosed with chronic phase CML over this period Without Gleevec: expect ~ 4,700 deaths With Gleevec: ~ 700 deaths ~ 4,000 lives saved (and counting)
- Discovery = find the root cause of the disease and a potential therapy Development = carrying out the studies required by Regulatory Agencies (FDA, Health Canada) in order to get a new therapy approved/ In addition to discovery and development drugs need to be commercialized in order to get to patients. This is in the hands of the biotech & pharmaceutical industries. LLS now has a comprehensive suite of research programs that covers the discovery (our research grant program) and development (the Therapy Acceleration Program) steps for finding new therapies and is partnering with the pharma industry to get new therapies to the health care providers.
- An Academic Concierge Project: The testing of 5000 existing, FDA approved, generic drugs for activity against acute leukemia by an academic investigator receiving one of our grants led to the discovery that a drug used to treat toe nail fungus, CPX, was active in blocking the growth of leukemia cell lines, leukemia in animal (mouse) models and AML cells from patients. Our goal: test the drug in a clinical trial against acute leukemia Process: LLS has assembled a development team to create an oral formulation of the existing product and an application to Health Canada to open a clinical trial Status: The oral formulation is complete. A Clinical Trial Application has been submitted to Health Canada. We expect a positive review and to be able to open a Phase I clinical trial in September. We moved this project forward with remarkable speed: concept to trial in 8 months!
- A high level review of the 400 active projects shows that LLS is supporting research across some of the most important areas for the development of targeted therapies, into fundamental cellular processes that regulate cell growth and survival and in virtually every therapeutic modality that applies to treatment of the blood cancers. Now lets focus on the 60 projects that are in the development stage.
- The bars and numbers above each step indicate the number of projects at each step in the drug development pathway (small molecule) in the LLS project portfolio. As might be expected, given our large discovery investment and previous neglect of development, most projects are at the earliest steps of this pathway. Given our desire to impact patient outcomes we want to better realize and maximize the value of this pipeline and have instituted the Therapy Acceleration Program to do so.